EP
TPST icon

Elkfork Partners’s Tempest Therapeutics TPST Stock Holding History

Elkfork Partners’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1
Closed -$2K – 1048
2018
Q4 		$2K Sell
1
-1
-50% -$2.06K ﹤0.01% 1015
2018
Q3 		$4K Buy
+2
New +$4.81K ﹤0.01% 1013

Other funds holding TPST

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
B
Bpifrance Maisons Alfort, Cedex, France $1.65B AUM 19.85% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

Elkfork Partners's TPST Position: Q1 2019 in Review

Elkfork Partners sold out of Tempest Therapeutics (TPST) in Q1 2019, closing a stake of 1 share — an estimated $2K sold.

Elkfork Partners first reported a position in TPST in Q3 2018 and held it in 2 quarters. The position peaked at $4K in Q3 2018. 30 funds tracked by Wall St. Rank hold TPST as of Q1 2019.

  • Elkfork Partners reported no remaining Tempest Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Elkfork Partners sold 1 Tempest Therapeutics share in Q1 2019, an estimated $2K.
  • Elkfork Partners first reported a position in Tempest Therapeutics in Q3 2018 and held it in 2 quarters.
  • Elkfork Partners's Tempest Therapeutics position peaked at $4K in Q3 2018.
  • 30 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2019.

Based on Elkfork Partners's 13F filing for Q1 2019, filed 13 May 2019.